Levelling the playing field through the London Network of the UK clinical trials accelerator platform

Area of Science:

• Medical Research
• Clinical Trials
• Genetics

Background:

• Cystic fibrosis (CF) is a severe genetic disorder impacting multiple organ systems and reducing life expectancy.
• Despite therapeutic advancements, a cure for CF remains elusive, necessitating ongoing clinical research.
• Numerous novel therapies are in development, with many clinical trials underway globally.

Purpose of the Study:

• To evaluate the effectiveness of the UK Cystic Fibrosis Trust's Clinical Trials Accelerator Platform (CTAP) in improving trial access for CF patients.
• To assess the collaborative efforts of London-based CF centers within the CTAP network.
• To identify strengths and areas for improvement in clinical trial delivery for chronic diseases.

Main Methods:

• Formation of a sub-network of four large and two smaller specialist CF centers in London.
• Implementation of a consortium-style collaboration to ensure equitable trial access and knowledge sharing.
• Review of practices through working group meetings and an online survey after four years of operation.

Main Results:

• The CTAP initiative successfully brought together 25 UK CF centers to enhance patient participation in clinical trials.
• The London sub-network facilitated broader trial portfolios and increased study options for UK patients.
• The review identified key strengths and areas for improvement in the CTAP program's operational practices.

Conclusions:

• The CTAP model demonstrates a successful national strategy for increasing access to CF clinical trials.
• Collaborative networks of specialist centers can improve research delivery and patient equity in chronic disease management.
• The findings offer valuable insights for other regions and chronic diseases aiming to enhance clinical trial participation.